Cemadotin

Drug Profile

Cemadotin

Alternative Names: LU 103793; NSC D 669356

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Cytostatic antibiotics; Oligopeptides; Peptide antibiotics
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 07 Sep 2006 Discontinued - Phase-II for Cancer in USA (IV-infusion)
  • 07 Sep 2006 Discontinued - Phase-II for Cancer in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top